The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
 
Elena Garralda
Consulting or Advisory Role - Alkermes; Anaveon; Boehringer Ingelheim; Bristol-Myers Squibb; Ellipses Pharma; Janssen; MAB Discovery; NeoMed; Roche; Seagen; TFS; Thermo Fisher Scientific
Speakers' Bureau - Lilly; MSD; Roche; Thermo Fisher Scientific
Research Funding - AstraZeneca/MedImmune; Novartis; Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Glycotope GmbH; Menarini; Merck Sharp & Dohme
 
Ammar Sukari
Stock and Other Ownership Interests - Merck
Honoraria - Merck Serono
Consulting or Advisory Role - Genentech
Speakers' Bureau - Eisai
 
Nehal J. Lakhani
Consulting or Advisory Role - Innovent Biologics
Research Funding - Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); Celgene (Inst); Celgene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Formation Biologics (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics; Innovent Biologics (Inst); Jounce Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Shattuck Labs (Inst); Symphogen (Inst); TaiRx, Inc. (Inst); Tesaro (Inst)
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Genentech/Roche (I); Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics
Research Funding - Abbvie (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Bolt Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Ionova (Inst); Klus Pharma (Inst); Lilly (Inst); Livzon (Inst); Merck (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Plexxikon (Inst); Sanofi (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Yanyan Lou
Consulting or Advisory Role - AstraZeneca; Janssen
Research Funding - Blueprint Medicines (Inst); Daiichi-Sankyo (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Tolero Pharmaceuticals (Inst)
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Talia Golan
Honoraria - MSD; Rafael Pharmaceuticals
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; MSD; Teva
Speakers' Bureau - Abbvie; AstraZeneca
Research Funding - AstraZeneca (Inst); MSD (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD
 
Ravit Geva
Honoraria - Bristol-Myers Squibb; Janssen; Lilly; Medison; Merck; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; BOL Pharma; Eisai; MSD; Novartis; Roche
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Medison; Merck
Other Relationship - BOL Pharma; Pyxis
 
Martin Wermke
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Cellex GmbH; Gemoab; ISA Pharmaceuticals; Macrogenics; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Cellex GmbH; Lilly; Novartis; Pfizer
Research Funding - Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer
 
Maria De Miguel
Honoraria - Janssen; MSD Oncology; Roche
(OPTIONAL) Uncompensated Relationships - Abbvie; Array BioPharma; Eisai; Genmab; Janssen; Lilly; MSD; Novartis; PharmaMar; Roche; Sanofi
 
John Palcza
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Sujata Jha
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Marya F. Chaney
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Jane Anne Healy
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Rocky Mountain Oncology Society
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst); Navire (Inst); Silicon Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biothera (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Exelixis (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Navire (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); poseida therapeutics (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Regeneron (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Sapience Therapeutics (Inst); Silicon Therapeutics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute